Insmed reported $526.79M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Cytokinetics USD 207.8M 7.22M Jun/2026
DBV Technologies USD 47.9M 2.2M Mar/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 526.79M 20.55M Jun/2026
Novartis USD 9.29B 507M Mar/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026